Immune checkpoint inhibitor-associated pneumonitis in patients with thoracic malignancy: Multicenter prospective observational study

Immune checkpoint inhibitor-associated pneumonitis in patients with thoracic malignancy: Multicenter prospective observational study - Immune checkpoint inhibitor-associated pneumonitis: Multicenter prospective observational study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039761

Enrollment

800

Registered

2020-04-01

Start date

2019-05-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thoracic malignancy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with thoracic malignancy who will receive nivolumab or pembrolizumab or atezolizumab

Exclusion criteria

Exclusion criteria: nothing

Design outcomes

Primary

Measure	Time frame
The incidence of immune checkpoint inhibitor-associated pneumonitis	—

Secondary

Measure	Time frame
Risk factors for the development of immune checkpoint inhibitor-associated pneumonitis	—

Countries

Japan

Contacts

Public ContactTakafumi Koyauchi

Hamamatsu University School of Medicine Second Division, Department of Internal Medicine

t.koya@hama-med.ac.jp053-435-2111

Outcome results